Potential new targets for drug development in severe asthma

Citation metadata

Date: Oct. 25, 2018
From: World Allergy Organization Journal(Vol. 11, Issue 1)
Publisher: BioMed Central Ltd.
Document Type: Report
Length: 4,933 words
Lexile Measure: 1470L

Document controls

Main content

Abstract :

In recent years there has been increasing recognition of varying asthma phenotypes that impact treatment response. This has led to the development of biological therapies targeting specific immune cells and cytokines in the inflammatory cascade. Currently, there are two primary asthma phenotypes, Type 2 hi and Type 2 lo, which are defined by eosinophilic and neutrophilic/pauci- granulocytic pattern of inflammation respectively. Most biologics focus on Type 2 hi asthma, including all four biologics approved for treatment of uncontrolled asthma in the United States -- omalizumab, mepolizumab, reslizumab, and benralizumab. Potential new targets for drug development are being investigated, such as IL-13, IL-4[alpha] receptor, CRTH2, TSLP, IL-25, IL-13, IL-17A receptor, and CXCR2/IL-8. This review will discuss the role of these molecules on the inflammatory response in uncontrolled asthma and the emerging biologics that address them. Through the delineation of distinct immunological mechanisms in severe asthma, targeted biologics are promising new therapies that have the potential to improve asthma control and quality of life. Keywords: Asthma, Severe asthma, Asthma therapeutics, Drug targets, Biologics

Source Citation

Source Citation   

Gale Document Number: GALE|A559858699